NCT02469181招募中不适用
Impact of Enzyme Replacement Therapy on Cardiac Function in Patients With Fabry's Cardiomyopathy : A Prospective Multi-modality Imaging Study Using Diastolic Stress Echocardiography, LV Vortex Flow and Cardiac MRI(RECAFTURE Trial)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Changes of peak exercise E(velocity of early)/E'(Early diastolic) by diastolic stress echocardiography
研究概览
简要总结
The purpose of this study is to evaluate the impact of ERT on LV diastolic function and flow in patients with Fabry's cardiomyopathy using diastolic stress echocardiography, LV vortex flow and CMR.
详细描述
- Objectives -The purpose of this study is to evaluate the impact of ERT on LV diastolic function and flow in patients with Fabry's cardiomyopathy using diastolic stress echocardiography, LV vortex flow and CMR.
- Primary / Secondary Endpoint 1) Primary endpoint
- Changes of peak exercise E/E' by diastolic stress echocardiography (RECAP-F STRESS trial) and LV vortex flow parameters (RECAP-F FLOW trial) at 1 year follow up.
- Secondary endpoint
-
Changes of extracellular volume by CMR(T1 mapping) at 1 year follow up (RECAP-F trial) ② Evaluation of the degree of the resting LV diastolic function ③ Other echo-parameters; LV mass index at baseline, 1 year follow up, reduction of peak exercise E/E prime at 1 year follow up
-
Changes of quality of life using questionnaire ⑤ Change of peak VO2, exercise time, AT by diastolic stress echocardiography at 1 year follow up ⑥ Change in T1 baseline(myo, ms) & T1 baseline(blood, ms) T1 postcontrast(myo, ms) & T1 baseline(blood, ms) by CMR
- Study Methods 1) Study Design : 28 patients with newly diagnosed genetically confirmed Anderson-Fabry's disease will undergo diastolic stress echocardiography, LV vortex flow analysis, and cardiac MRI before enzyme replacement therapy(ERT) (baseline study) and after 1 year of treatment with agalsidese beta at the dose of 1mg/kg (follow-up study).
- Study procedures : Examinations as described below will be done before ERT and 1 year later
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 16 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged 16~75 years with Fabry's disease who were confirmed by enzyme assay and gene study
- •All patients should have LV hypertrophy in 2D echocardiography (end diastolic septum and posterior wall thickness ≥12mm)
- •Patients provided with the written, informed consent to participate in this study
排除标准
- •Contraindication for agalsidase beta enzyme replacement treatment
- •Patients who cannot perform supine bicycle stress echocardiography, contrast echocardiography or cardiac MRI
- •Hemodynamically significant valvular heart disease or arrythmias
- •History of acute myocardial infarction or congestive heart failure with reduced LV ejection fraction of less than 35%
- •CVA in the prior 6 months
- •Scheduled or planned surgery in the next 6 months
- •Chronic liver cirrhosis
- •Allergy to contrast agent (Definity®, Lantheus Medical Imaging, North Billerica, MA, USA)
结局指标
主要结局
Changes of peak exercise E(velocity of early)/E'(Early diastolic) by diastolic stress echocardiography
时间窗: 1 year after the echocardiography
次要结局
- Change of peak VO2 by diastolic stress echocardiography(1 year after the echocardiography)
- Change of peak exercise time by diastolic stress echocardiography(1 year after the echocardiography)
- Changes of extracellular volume by Cardiac MRI(CMR)(1 year after the CMR)
- LV(left ventricular) vortex flow analysis by contract echocardiography(1 year after the echocardiography)
研究者
研究点 (1)
Loading locations...
相似试验
Enrolling By Invitation
不适用
Effect of Enzyme Replacement Therapy on Cardiac Function in Children With Gaucher Disease Type 3Gaucher Disease Type 3NCT06627543Noha Osman44
已完成
不适用
Efficacy and safety of enzyme replacement therapy for MPS I with 100 I.U./Kg recombinant human a-L-iduronidase (ALDURAZYME™).Mucopolysaccharidose type I.NL-OMON21663CVZ35
已完成
不适用
Changes in Cardiac Functions in Patients Treated With Parathyroidectomy for Secondary HyperparathyroidismSecondary HyperparathyroidismMyocardial DysfunctionNCT06187480Mersin University37
进行中（未招募）
1 期
Effect of timing of enzyme replacement therapy (Creon®) at meals on fat malabsorption in adult patients with cystic fibrosis - a cross-over trialGI pains and fat malabsorption in cysticfibrosis patients with pancreas insufficiencyMedDRA version: 20.1Level: LLTClassification code 10025479Term: Malabsorption syndromeSystem Organ Class: 100000004856EUCTR2019-004940-31-DKTerese Katzenstein30
Unknown
4 期
Target Controlled Infusion of Etomidate or Propofol for Anesthesia of Thoracoscopic Mitral Valve Replacement SurgeryHemodynamic InstabilityDeliriumNCT02644980Xijing Hospital110